Selection of an alternative cryoagent to cover the thermal load in the WBC systems
DOI: 10.17586/1606-4313-2022-21-1-76-82
UDC 621.59
Baranov Aleksandr Yu., Novitskaya Anna V., Sokolova E.V., Chubova Sofia D., Ziyavidinov Anvar M.
Keywords: general cryotherapy, WBC, cryoagent, liquefied natural gas, LNG, COVID-19, heat of regasification.
UDC 621.59
Selection of an alternative cryoagent to cover the thermal load in the WBC systems
For citation: Baranov A.Yu., Vasilenok A.V., Sokolova Е.V., Chubova S.D., Ziyavidinov A.M. Selection of an alternative cryoagent to cover the thermal load in the WBC systems. Journal of International Academy of Refrigeration. 2022. No 1. p. 76-82. DOI: 10.17586/1606-4313-2022-21-1-76-82
Abstract
General cryotherapy (WBC) is a medical technology with a wide range of indications for use, including as a means of rehabilitation of patients who have had COVID-19. The mass application of cryotherapy technology for rehabilitation requires large amounts of cryoagent (liquid nitrogen). The most successful is the use of systems in which imported cryoagent, liquid nitrogen, or air is used to cover the thermal load. Due to the increase in oxygen consumption in clinics treating COVID-19, the production of liquid nitrogen has decreased and prices for this cryoproduct have increased. The limited availability of liquid nitrogen prevents the widespread use of WBC for the rehabilitation of patients who have had COVID-19. New sources of liquid nitrogen or an alternative cryoagent are needed to ensure the operation of cryotherapy units. Under the conditions of expanding consumption of liquefied natural gas (LNG), it is rational to use the heat of regasification of this cryoproduct for the implementation of low-temperature technologies. LNG production exceeds 300 million tons per year. At the same time, LNG is used only after conversion to a gaseous state. The specific heat of LNG regasification reaches 900 kJ/kg, which is two times more than the heat of nitrogen liquefaction. The boiling point of LNG at atmospheric pressure allows cryostating devices for WBC at an optimal temperature level (130–140 K). It is shown that the direct use of LNG as a cryo-agent is possible, but only in some cases. For widespread use of the heat of regasification, it is advisable to produce a secondary cryoagent, liquid air or nitrogen of low purity at the place of gas supply to the distribution network. This cryoproduct can be used as a cryoagent for general cryotherapy units or for the implementation of other low-temperature technologies.
Abstract
General cryotherapy (WBC) is a medical technology with a wide range of indications for use, including as a means of rehabilitation of patients who have had COVID-19. The mass application of cryotherapy technology for rehabilitation requires large amounts of cryoagent (liquid nitrogen). The most successful is the use of systems in which imported cryoagent, liquid nitrogen, or air is used to cover the thermal load. Due to the increase in oxygen consumption in clinics treating COVID-19, the production of liquid nitrogen has decreased and prices for this cryoproduct have increased. The limited availability of liquid nitrogen prevents the widespread use of WBC for the rehabilitation of patients who have had COVID-19. New sources of liquid nitrogen or an alternative cryoagent are needed to ensure the operation of cryotherapy units. Under the conditions of expanding consumption of liquefied natural gas (LNG), it is rational to use the heat of regasification of this cryoproduct for the implementation of low-temperature technologies. LNG production exceeds 300 million tons per year. At the same time, LNG is used only after conversion to a gaseous state. The specific heat of LNG regasification reaches 900 kJ/kg, which is two times more than the heat of nitrogen liquefaction. The boiling point of LNG at atmospheric pressure allows cryostating devices for WBC at an optimal temperature level (130–140 K). It is shown that the direct use of LNG as a cryo-agent is possible, but only in some cases. For widespread use of the heat of regasification, it is advisable to produce a secondary cryoagent, liquid air or nitrogen of low purity at the place of gas supply to the distribution network. This cryoproduct can be used as a cryoagent for general cryotherapy units or for the implementation of other low-temperature technologies.
Keywords: general cryotherapy, WBC, cryoagent, liquefied natural gas, LNG, COVID-19, heat of regasification.
Русский
English
